The Egyptian Journal of Neurology, Psychiatry and Neurosurgery

Table 7 A MGS values for patient with a favorable neurological outcome (n = 21) throughout study duration. B Comparison between MGS values for patient with a favorable neurological outcome (n = 21) throughout study duration

From: The use of dexamethasone therapy for conservative management of chronic subdural hematomas: a question about efficacy and safety

MGS	Day 1 (%)	Day 14 (%)	1 month (%)	3 months (%)	6 months (%)
0	0 (0.0)	2 (9.5)	8 (38.1)	11 (52.4)	17 (81.0)
1	11 (52.4)	18 (85.7)	13 (61.9)	10 (47.6)	4 (19.0)
2	10 (47.6)	1 (4.8)	0 (0.0)	0 (0.0)	0 (0.0)

Measurements	Chi-square test	p-value
Day 1 vs. Day 14	11.053	0.004*
Day 1 vs. 1 M	18.167	< 0.001**
Day 1 vs. 3 M	21.048	< 0.001**
Day 1 vs. 6 M	30.267	< 0.001**
Day 14 vs. 1 M	5.406	0.067
Day 14 vs. 3 M	9.516	0.009*
Day 14 vs. 6 M	21.751	< 0.001**
1 M vs. 3 M	0.384	0.535
1 M vs. 6 M	6.325	0.012*
3 M vs. 6 M	2.679	0.102

Using: Chi-square test
GCS Markwalder Grading Scale, n number of patients, M months after protocol initiation
p-value > 0.05 is insignificant, *p-value < 0.05 is significant, **p-value < 0.001 is highly significant

Back to article page